<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463996</url>
  </required_header>
  <id_info>
    <org_study_id>MR-Center-001</org_study_id>
    <nct_id>NCT00463996</nct_id>
  </id_info>
  <brief_title>MRI in Staging Ovarian Cancer Using MRI Contrast Agent</brief_title>
  <official_title>VÃ¦rdien af MRI Til Staging af c.Ovarii-et Prospektivt Studie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can MRI be used to stage ovarian cancer?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Staging of ovarian cancer can best be performed with CT or MRI compared to ultrasound.
      Studies have shown an increase in pos. predictive value by adding contrast i.v. to the
      MR-examination protocol. We compare staging of ovarian cancer by 1.MRI without contrast
      (standard method) to 2.MRI with contrast agent i.v. (new method)in the same patient. Golden
      standard are findings at operation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">April 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Case Control</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Ovarian Cancer</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspicion of ovarian cancer

        Exclusion Criteria:

          -  recurrence of disease

          -  contraindication to MRI, contrast agent

          -  inoperable patients for other reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liselotte Ibsen, doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, BDA, Skejby</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liselotte Ibsen, doc</last_name>
    <phone>+4589495201</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erik Lundorf, consultant</last_name>
    <phone>+4589495251</phone>
    <email>elu@sks.aaa.dk</email>
  </overall_contact_backup>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>April 18, 2007</last_update_submitted>
  <last_update_submitted_qc>April 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2007</last_update_posted>
  <keyword>Ovarian cancer</keyword>
  <keyword>MRI</keyword>
  <keyword>Contrast agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

